MedTrace Logo

Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan

NCT01075945 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2010-02-25

No results posted yet for this study

Summary

Dihydroartemisinin- Piperaquine is not inferior to artemether-lumefantrine

Conditions

Interventions

DRUG

Dihydroartemisinin- piperaquine

three tablets per day

DRUG

artemether- lumefantrine

twenty tablet in eight doses

Sponsors & Collaborators

  • Southeast University, China

    collaborator OTHER

  • University of Khartoum

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Sudan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075945 on ClinicalTrials.gov